Efficacy and safety of the natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis
Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ
Published in Journal of Neural Transmission
Methodology
Updated meta-analysis of randomised placebo-controlled trials of huperzine A with MMSE and ADL as primary outcomes
Key Findings
Huperzine A improved MMSE by roughly 2.8 points and ADL scores versus placebo, with adverse events comparable to placebo.
Conclusions
Huperzine A appears to improve cognitive measures in Alzheimer's disease with acceptable tolerability.
Limitations
Trial quality limited; possible publication bias in the source literature.
Supplements Studied
Huperzine A improved MMSE by roughly 2.8 points and ADL scores versus placebo.
Outcomes Measured
Huperzine A improved MMSE by roughly 2.8 points versus placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.